The Individual Clinical Review process is being phased out and a more streamlined Exceptional Access Program (EAP) has been created to handle requests for drugs that are not listed in the Formulary. For more information please visit the EAP section.
Pursuant to section 15 of O.Reg. 201/96 made under the Ontario Drug Benefit Act (ODBA), the Executive Officer (EO) has entered into agreements with manufacturers to establish Drug Benefit Prices (DBPs) for products reimbursed under the Exceptional Access Program (EAP).
For the following products reimbursed under the EAP, the Health Network System (HNS) will adjudicate claims at the DBP listed below.
| DIN |
Trade Name |
Strength |
Dosage Form |
DBP |
| Effective Date : January 19, 2012 |
| 02284227 |
Nexavar |
200mg |
Tablet |
$46.0088 |
| Effective Date : January 4, 2012 |
| 02215136 |
Saizen |
3.3mg |
Vial |
$144.9000 |
| 02237971 |
Saizen |
5mg |
Vial |
$217.5200 |
| 02272083 |
Saizen ClickEasy |
5.83mg/mL |
8.8mg Vial |
$348.0300 |
| 02350122 |
Saizen |
5.83mg/mL |
6mg/cartridge |
$261.0000 |
| 02350130 |
Saizen |
8mg/mL |
12mg/cartridge |
$522.0000 |
| 02350149 |
Saizen |
8mg/mL |
20mg/cartridge |
$870.0000 |
| Effective date: December 28, 2011 |
| 02260565 |
Xolair |
150mg |
Powder for solution injection sc (5mL vial) |
$600.0000 |
| Effective date : December 5, 2011 |
| 02293129 |
Sprycel |
20mg |
Oral tablet |
$35.7500 |
| 02293137 |
Sprycel |
50mg |
Oral tablet |
$71.9500 |
| 02293145 |
Sprycel |
70mg |
Oral tablet |
$78.9000 |
| Effective date : November 14, 2011 |
| 02326442 |
Tykerb |
250mg |
Tablet |
$23.5000 |
| Effective date : November 7, 2011 |
| 02269201 |
Avonex PS |
30mcg/0.5mL |
Prefilled syringe |
$399.0250 |
| 09857395 |
Avonex Pen |
30mcg/0.5mL |
Prefilled autoinjector pen |
$399.0250 |
| Effective date : October 28, 2011 |
| 02370816 |
Victrelis |
200mg |
Cap |
$12.5000 |
| 02371448 |
Victrelis Triple |
200mg Cap & 200mg Cap & 80mcg Inj Pd |
168 Caps &
56 Caps &
2 Redipens, Combination Kit |
$2,652.5500 |
| 02371456 |
Victrelis Triple |
200mg Cap & 200mg Cap & 100mcg Inj Pd |
168 Caps &
56 Caps &
2 Redipens, Combination Kit |
$2,652.5500 |
| 02371464 |
Victrelis Triple |
200mg Cap & 200mg Cap & 120mcg Inj Pd |
168 Caps &
70 Caps &
2 Redipens, Combination Kit |
2,726.0000 |
| 02371472 |
Victrelis Triple |
200mg Cap & 200mg Cap & 150mcg Inj Pd |
168 Caps &
84 Caps &
2 Redipens, Combination Kit |
$2,726.0000 |
| 09857396 |
Victrelis Triple |
200mg Cap & 200mg Cap & 150mcg Inj Pd |
168 Caps &
98 Caps &
2 Redipens, Combination Kit |
$2,726.0000 |
| Effective date : October 27, 2011 |
| 02357119 |
Vpriv ® |
400U |
Vial |
$1955.0000 |
| Effective date : October 26, 2011 |
| 09857394 |
Enbrel Sureclick® |
50mg/mL |
Prefilled autoinjection |
$368.9075 |
| Effective date : October 19, 2011 |
| 02287145 |
Fosrenol® |
250mg |
Chewable tab |
$1.0527 |
| 02287153 |
Fosrenol® |
500mg |
Chewable tab |
$2.1053 |
| 02287161 |
Fosrenol® |
750mg |
Chewable tab |
$3.1682 |
| 02287188 |
Fosrenol® |
1000mg |
Chewable tab |
$4.2004 |
| Effective date : October 11, 2011 |
| 02299909 |
Cubicin |
500mg/10mL |
Vial powder for injection |
$174.0000 |
| Effective date : September 16, 2011 |
| 02248676 |
Iressa |
250mg |
Tablet |
$73.3000 |
| Effective date : September 8, 2011 |
| 02349124 |
Effient |
10mg |
Tablet (supplied as blister pack of 30 tablets) |
$2.6600 |
| Effective date : September 12, 2011 |
| 02318253 |
Rebif |
66ug |
Multi-Dose Cartridge |
$363.6300 |
| 02318261 |
Rebif |
132ug |
Multi-Dose Cartridge |
$442.6800 |
| 02237319 |
Rebif |
22mcg |
Pre-Filled Syringe |
$121.2100 |
| 02237320 |
Rebif |
44mcg |
Pre-Filled Syringe |
$147.5600 |
| Effective date : August 18, 2011 |
| 01968017 |
Neupogen |
300mcg/mL |
1mL vial injection |
$184.4600 |
| 09853464 |
Neupogen |
480mcg/1.6mL |
injection |
$295.1360 |
| Effective date : August 17, 2011 |
| 02357615 |
Vimpat |
50mg |
F.C. Tablet |
$2.3200 |
| 02357623 |
Vimpat |
100mg |
F.C. Tablet |
$3.3200 |
| 02357631 |
Vimpat |
150mg |
F.C. Tablet |
$4.3200 |
| 02357658 |
Vimpat |
200mg |
F.C. Tablet |
$5.3200 |
| Effective date : July 22, 2011 |
| 02322285 |
Soliris |
10mg/mL |
30mL vial for IV injection |
$6,742.5000 |
Effective date : May 31, 2011 |
| 02280795 |
Sutent |
12.5mg |
Cap |
$63.1525 |
| 02280809 |
Sutent |
25mg |
Cap |
$126.3043 |
| 02280817 |
Sutent |
50mg |
Cap |
$252.6089 |
Effective date : May 20, 2011 |
| 02350092 |
Actemra |
20mg/mL |
Concentrate sol for infusion, 80mg/4mL vial |
$179.2000 |
| 02350106 |
Actemra |
20mg/mL |
Concentrate sol for infusion, 200mg/10mL vial |
$448.0000 |
| 02350114 |
Actemra |
20mg/mL |
Concentrate sol for infusion, 400mg/20mL vial |
$896.0000 |
| Effective date: May 19, 2011 |
| 2282097 |
Orencia |
250mg/15mL |
Vial |
$454.6000 |
| 02242572 |
Actos |
15mg |
Tab |
$2.3783 |
| 02242573 |
Actos |
30mg |
Tab |
$3.3319 |
| 02242574 |
Actos |
45mg |
Tab |
$5.0099 |
| 02258595 |
Humira |
40mg/0.8mL |
Pre-Filled Syr |
$715.1200 |
| 09857294 |
Humira |
40mg/0.8mL |
Pre-Filled Pen |
$715.1200 |
| 02287420 |
Exjade |
125mg |
Tab for Susp |
$10.2039 |
| 02287439 |
Exjade |
250mg |
Tab for Susp |
$20.4075 |
| 02287447 |
Exjade |
500mg |
Tab for Susp |
$40.8154 |
| 02286386 |
Tysabri |
300mg/15mL |
Vial |
$2,986.0300 |
| Effective date : May 18, 2011 |
| 02322854 |
Nplate |
250mcg/0.5mL |
Powder for solution for injection |
$897.5000 |
| 02322862 |
Nplate |
500mcg/1mL |
Powder for solution for injection |
$1795.0100 |
| Effective date: February 11, 2011 |
| 02339528 |
Afinitor |
10mg |
Tab |
$186.0000 |
| 02337819 |
Extavia |
0.3mg/vial |
Powder for sc injection |
$99.3593 |
| Effective date: February 4, 2011 |
| 02315874 |
Tasigna |
200mg |
Cap |
$38.7147 |
| Effective date: January 31, 2011 |
| 02338327 |
Adcirca |
20mg |
Tab |
$13.0725 |
| Effective date: December 24, 2010 |
| 02295709 |
Suboxone |
8mg/2mg |
Tab |
$4.7300 |
| Effective date : November 21, 2010 |
| 02245619 |
Copaxone |
20mg/mL |
Pre-Filled Syringe |
$43.2000 |
| Effective date : October 18, 2010 |
| 02324784 |
Simponi |
50mg/0.5mL |
Auto-Injector |
$1447.0000 |
| 02324776 |
Simponi |
50mg/0.5mL |
Pre-Filled Syringe |
$1447.0000 |
| Effective date : October 18, 2010 |
| 02244016 |
Remicade |
100mg/10mL |
Injection |
$940.0000 |
| 09852956 |
Remicade |
100mg/10mL |
Injection (Compounded) |
$940.0000 |
| Effective date : September 30, 2010 |
| 02331675 |
Cimzia |
200mg/mL |
Pre-Filled Syringe |
$664.5100 |
| Effective date : September 9, 2010 |
| 02242903 |
Enbrel |
25mg/Vial |
Inj Pd-Vial Pk |
$184.4525 |
| 02250519 |
Zavesca |
100mg |
Cap |
$108.5479 |
| Effective date : March 2, 2010 |
| 02241093 |
Temodal |
5mg |
Cap |
$7.4174 |
| 02241094 |
Temodal |
20mg |
Cap |
$29.6694 |
| 02241095 |
Temodal |
100mg |
Cap |
$148.3468 |
| 02312794 |
Temodal |
140mg |
Cap |
$207.6863 |
| 02312816 |
Temodal |
180mg |
Cap |
$267.0238 |
| 02241096 |
Temodal |
250mg |
Cap |
$370.8565 |
| Effective date : February 10, 2010 |
| 02284642 |
Azilect |
0.5mg |
Tab |
$7.0000 |
| 02284650 |
Azilect |
1mg |
Tab |
$7.0000 |
| Effective date : January 5, 2010 |
| 01981501 |
Botox |
100U/Vial |
Pd Inj-100U
Vial Pk |
$357.0000 |
| Effective date : October 8, 2009 |
| 02169649 |
Betaseron |
0.3mg/Vial |
Injection |
$110.0000 |
| Effective date : July 22, 2009 |
| 02317699 |
Revlimid |
15mg |
Cap |
$382.0000 |
| 02317710 |
Revlimid |
25mg |
Cap |
$424.0000 |
| Effective date : June 11, 2009 |
| 02284863 |
Myozyme |
50mg/vial |
Lyophylized Powder |
$840.3100 |
| Effective date : June 1, 2009 |
| 02241112 |
Avandia |
2mg |
Tab |
$1.3755 |
| 02241113 |
Avandia |
4mg |
Tab |
$2.1584 |
| 02241114 |
Avandia |
8mg |
Tab |
$3.0866 |
| Effective date : May 27, 2009 |
| 02296314 |
Elaprase |
2mg/mL |
3mL Vial |
$3,800.00 |
| Effective Date : January 19, 2009 |
| 02304899 |
Revlimid |
5mg |
Capsule |
$340.0000 |
| 02304902 |
Revlimid |
10mg |
Capsule |
$361.0000 |
| Effective Date : December 3, 2008 |
| 2274728 |
Enbrel |
50mg/mL |
Inj Pref Syr |
$364.2800 |
| Effective Date : November 17, 2008 |
| 02284227 |
Nexavar |
200mg |
Tablet |
$45.0625 |
Until further notice, for all other products reimbursed under the EAP, pharmacists will continue to be reimbursed their acquisition cost plus the applicable markup (currently 8%).